等待开盘 11-05 09:30:00 美东时间
-2.950
-3.01%
今日重点评级关注:康托·菲茨杰拉德:维持Cabaletta Bio"超配"评级,目标价从15美元升至30美元;HC Wainwright & Co.:维持Invivyd"买入"评级,目标价从5美元升至10美元
11-03 20:20
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Insight业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 净营收20亿美元,同比下降4% - 产品营收同比下降6%,主要由于本地软件营收下降19% - 商业客户营收增长5%,但被企业和大型企业客户营收下降所抵消 - 硬件营收连续第三个季度增长1% **利润率表现:** - 毛利率达到创纪录的21.7%,同比增长100个基点 - 硬件毛利率环比持平,但硬件毛利润同比下降5% **各业务线毛利润:** - 核心服务毛利润7900万美元,同比下降3% - 云服务毛利润1.3亿美元,同比增长7% - 整体毛利润基本
10-31 12:05
-SEC Filing
10-30 20:28
Insight Enterprises (NASDAQ:NSIT) lowers FY2025 Adj EPS guidance from $9.70-$10.10 to $9.60-$9.90 vs $9.74 analyst estimate..
10-30 20:02
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
今日重点评级关注:HC Wainwright & Co.:维持Unicycive Therapeutics"买入"评级,目标价从9美元升至22美元;花旗:维持Arcus Biosciences"买入"评级,目标价从54美元升至56美元
10-30 14:22
Barrington Research analyst Vincent Colicchio maintains Insight Enterprises (NASDAQ:NSIT) with a Outperform and maintains $164 price target.
10-29 19:42
Insight Enterprises Inc's (NYSE:NSIT) short interest as a percent of float has ...
10-27 22:00
Insight Enterprises (NASDAQ:NSIT) has outperformed the market over the past 15 ...
10-18 07:45
Insight Enterprises Inc's (NYSE:NSIT) short interest as a percent of float has ...
10-03 04:01